TWI776985B - Use of labisia pumila extract for improving skin elasticity, strength or stability - Google Patents

Abstract

The present invention provides a use of Labisia Pumila extract for enhancing the gene expression of Transglutaminase, Keratin, Aquaporin, Filaggrin, Mothers against decapentaplegic homolog, Glucocerebrosidase, and Hyaluronan synthase and improving the appearance of the skin. The Labisia Pumila extract can effectively enhancing the gene expression of TGM, KRT, AQP, FLG, SMAD, GBA, and /or HAS, and can effectively reduce wrinkles, melanin and water loss of the skin. The Labisia Pumila extract is prepared by extracting Labisia Pumila using water, alcohols, or mixtures of water and alcohols as solvents.

Description

Use of Kacip Fatima extract to improve skin elasticity, strength or stability

The present invention relates to the use of a Kacip Fatima extract, especially a Kacip Fatima extract for enhancing the expression of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene and HAS gene. performance.

The epidermis is the outermost layer of the skin. From the outside to the inside, it is the stratum corneum, the granular layer, the spinous layer and the basal layer. The epidermal layer is mainly formed by the continuous upward differentiation of undifferentiated cylindrical keratinocytes in the basal layer. This process called keratinization. The water content in keratinocytes is high. As the cells undergo upward metabolic differentiation, the shape of keratinocytes gradually becomes flat, and the nucleus and organelles begin to degenerate and shrink, and dead cells without nuclei and organelles are formed in the stratum corneum. The main function of the epidermis is to retain water for the skin and form a skin barrier to resist various external damages. The outermost layer of the epidermis is composed of a weakly acidic sebum film and a stratum corneum such as a brick wall structure. Moisture and oil, resist the invasion of germs on the skin surface, and resist external foreign bodies and ultraviolet light damage, which have a very important protective effect on the human body.

The stratum corneum in the epidermis, although its keratinocytes are dead cells, its main component is keratin, keratin can absorb water to keep the skin moist, and keratinocytes also secrete substances such as hyaluronic acid as intercellular substance, In order to maintain the structural integrity of the skin barrier of the epidermis to prevent the loss of skin moisture and form a complete protection. When the skin is exposed to stimuli such as cold or hot environment and ultraviolet light, it will cause the keratinocytes to be unable to maintain the normal metabolic cycle, and the water retention capacity of the skin will also decrease, and This leads to damage to the epidermal barrier of the skin, making the skin rough, dry and desquamated, vulnerable to irritation, and sensitive to redness. Therefore, the health and water retention capacity of the stratum corneum is really important to resist external damage.

In addition, in recent years, in order to meet people's pursuit of fair skin and spot reduction, various whitening products that inhibit the formation of melanin or lighten spots have been developed on the market. Chemicals or environmental hormones that allow consumers to unknowingly use ingredients that can harm skin and affect health.

Based on the above, in response to the modern trend of focusing on natural health, in order to improve the problem that the skin becomes fragile and sensitive due to the damage of keratinocytes and the decline of water-retaining ability, we have developed a kind of skin that can effectively make keratinocytes secrete more moisturizing factors. It is indeed necessary to maintain the arrangement of keratinocytes, maintain the integrity of the stratum corneum structure, improve the skin barrier function, and take into account the needs of skin whitening.

For this reason, one of the objects of the present invention is to provide a kind of Kacip Fatima extract for preparing and improving transglutaminase (Transglutaminase, TGM ) gene, keratin (Keratin, KRT ) gene, aquaporin (Aquaporin, AQP ) gene, polykeratin microfilament (Filaggrin, FLG ) gene, parental antibody Dpp homolog (Mothers against decapentaplegic homolog, SMAD ) gene, Glucocerebrosidase (Glucocerebrosidase, GBA ) gene, and/or hyaluronic acid synthase (Hyaluronan synthase, HAS ) use of the composition of gene expression, wherein the Kacip Fatima extract is obtained by extracting Kacip Fatima with a solvent, and the solvent is water, alcohol, or a mixture of alcohol and water; Wherein the composition is a medicine, a food or a skin care product.

Another object of the present invention is to provide the use of a Kacip Fatima extract for preparing a composition for beautifying skin appearance, wherein the Kacip Fatima extract is obtained by extracting a Kacip Fatima with a solvent , the solvent is water, alcohol, or a mixture of alcohol and water; wherein the composition is a medicine, a food or a skin care product.

In one embodiment of the present invention, the weight ratio of the solvent to the Kacip Fatima is 5-20:1-5, and the extraction temperature is 50°C-100°C.

In another embodiment of the present invention, the TGM gene is a transglutaminase 1 (Transglutaminase 1, TGM1 ) gene; the KRT gene is a keratin 1 (Keratin1, KRT1 ) gene, a keratin 10 (Keratin10, KRT10 ) gene and keratin 14 (Keratin14, KRT14 ) gene; the AQP gene is aquaporin 3 (Aquaporin 3, AQP3 ) gene; SMAD gene is a mother against decapentaplegic homolog 1 (Mothers against decapentaplegic homolog 1, SMAD1 ) gene; And the HAS gene comprises hyaluronan synthase 2 (Hyaluronan synthase 2, HAS2 ) gene and hyaluronan synthase 3 (Hyaluronan synthase 3, HAS3 ) gene, and the concentration of the Kacip Fatima extract is at least 0.125mg/mL.

In another embodiment of the present invention, the beautifying skin appearance is reducing skin wrinkles, reducing skin melanin and/or reducing skin moisture loss, and the concentration of the Kacip Fatima extract is at least 0.125 mg/mL.

The Kacip Fatima extract of the present invention can effectively improve the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, and can improve It can effectively reduce skin wrinkles, reduce skin melanin and reduce skin moisture loss. It can improve the expression of skin TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene, as well as skin anti-wrinkle, whitening, and moisturizing. To make the skin form more moisturizing factors, maintain the integrity of the stratum corneum structure, and improve the skin barrier function. Therefore, the Kacip Fatima extract of the present invention can be used to prepare a composition for enhancing the expression of skin TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene and beautifying skin appearance, And the composition is a medicine, a food or a skin care product, which can be administered to an individual by oral administration, skin application and the like.

The embodiments of the present invention will be further described below. The following examples are used to illustrate the present invention, but not to limit the scope of the present invention. Anyone who is familiar with this technique, without departing from the spirit and scope of the present invention, Some changes and modifications can be made, so the protection scope of the present invention should be determined by the scope of the appended patent application.

Fig. 1 is a bar graph showing the effect of the Kacip Fatima extract of the present invention in enhancing the expression levels of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene. *p<0.05;**p<0.01;***p<0.001.

Figure 2 is a bar graph showing the effect of the Kacip Fatima extract of the present invention in reducing skin wrinkles. *p<0.05.

3 is a bar graph showing the effect of the Kacip Fatima extract of the present invention in reducing skin melanin. *p<0.05; #p<0.05.

Figure 4 is a bar graph showing the effect of the Kacip Fatima extract of the present invention in reducing skin moisture loss. *p<0.05.

definition

Numerical values used herein are approximations and all experimental data are expressed within 20%, preferably within 10%, and most preferably within 5%.

Statistical analysis was performed using Excel software. Data are presented as mean ± standard deviation (SD), and differences between them were analyzed by Student's t -test .

According to the present invention, Labisia Pumila is a perennial herb of the Primulaceae family, and the English name is Kacip Fatimah, originating in Malaysia, and Kacip Fatimah is translated from Malay Kacip fatimah . Kaqi Fatima grows in low bushes, with solitary or rarely branched stems and hairy roots, its leaves are oblong with fine hairs below, about 20-40 cm long, the inflorescence is brown, about 5-6 cm. Kacip Fatima can be used to improve menstrual pain and treat flatulence.

As used herein, the term "Kach Fatima extract" means that Kacip Fatima is extracted with a solvent in a ratio of 1-5:5-20 (w/w) for a specific time and temperature.

As used herein, the term "beautifying the appearance of the skin" means preventing, slowing down the aging phenomena of human skin appearance, such as: for example: wrinkles and loss of elasticity, etc.; improving the fairness and radiance of human skin appearance, for example: reducing skin Melanin content and production, etc; The extent to which this is assessed will depend upon a number of factors known to those skilled in the art, such as the general state of the consumer, age, gender, and the like.

According to the present invention, pharmaceutical products can be manufactured into a dosage form suitable for parenterally or topically administration using techniques well known to those skilled in the art, including, but not limited to: injections (injection) [eg, sterile aqueous solution or dispersion], sterile powder, external preparation, and the like.

According to the present invention, the pharmaceutical product may further comprise a pharmaceutically acceptable carrier which is widely used in pharmaceutical manufacturing technology. For example, the pharmaceutically acceptable carrier may comprise one or more agents selected from the group consisting of: solvent, buffer, emulsifier, suspending agent, decomposer ), disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent , gelling agent (gelling agent), preservative (preservative), wetting agent (wetting agent), lubricant (lubricant), absorption delaying agent (absorption delaying agent), liposome (liposome) and and the like. The selection and quantity of these reagents are within the scope of the expertise and routine skills of those skilled in the art.

According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), Aqueous solutions containing alcohol and combinations thereof.

According to the present invention, the medicinal product may be administered by a parenteral route selected from the group consisting of: subcutaneous injection, intraepidermal injection, intradermal injection Intradermal injection and intralesional injection.

According to the present invention, the medicinal product may be manufactured into an external preparation suitable for topical application to the skin using techniques well known to those skilled in the art, including, but not limited to: emulsions, gels Gel, ointment, cream, patch, liniment, powder, aerosol, spray, lotion, milk Serum, paste, foam, drop, suspension, salve and bandage.

According to the present invention, the external preparation is prepared by mixing the medicinal product of the present invention with a base well known to those skilled in the art.

According to the present invention, the substrate may comprise one or more additives selected from the group consisting of water, alcohols, glycols, hydrocarbons (such as petroleum, jelly) and white petrolatum], waxes [such as paraffin and yellow wax], preserving agents, antioxidants, surfactants, absorption enhancers absorption enhancers, stabilizing agents, gelling agents [such as carbopol ^{® 974P} , microcrystalline cellulose and carboxymethylcellulose] , active agents, humectants, odor absorbers, fragrances, pH adjusting agents, chelating agents, emulsifiers, occlusives occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants and propellants Agents (propellants) and so on. The selection and quantity of these additives are within the professional and routine skills of those skilled in the art.

According to the present invention, the skincare product may further comprise an acceptable adjuvant which is widely used in skincare product manufacturing techniques. For example, the acceptable adjuvant may contain one or more agents selected from the group consisting of solvents, gelling agents, active agents, preservatives, antioxidants, screening agents, chelating agents, surfactants, dyes Coloring agents, thickening agents, fillers, fragrances and odor absorbers. The selection and quantity of these reagents are within the scope of the expertise and routine skills of those skilled in the art.

According to the present invention, the skin care product can be manufactured into a form suitable for skincare or makeup using techniques well known to those skilled in the art, including, but not limited to: aqueous solution, water -Aqueous-alcohol solution or oily solution, emulsion in oil-in-water type, water-in-oil type or complex type, coagulation glue, ointment, cream, mask, patch, pack, liniment, powder, aerosol, spray, lotion, serum, paste, foam, dispersion, drops, mousse ( mousse), sunblock, tonic water, foundation, makeup remover products, soap and other body cleansing products.

According to the present invention, skin care products may also be used in combination with one or more external use agents with known activity selected from the group consisting of whitening agents (such as vitamin A) tretinoin, catechin, kojic acid, arbutin and vitamin C], humectants, anti-inflammatory agents, bactericides, ultraviolet absorbers, plant extracts [such as aloe extract], skin nutrients, anesthetics, anti-acne agents, antipruritics, pain relievers analgesics, antidermatitis agents, antihyperkeratolytic agents, anti-dry skin agents, antipsoriatic agents, antiaging agents , antiwrinkle agents, antiseborrheic agents, wound-healing agents, corticosteroids and hormones. The selection and quantity of these topical preparations fall within the scope of the professionalism and routine skills of those who are familiar with the technology.

According to the present invention, the food product can be regarded as a food additive, which is added during the preparation of raw materials by conventional methods, or added during the production process of the food, and is formulated with any edible material for Food products consumed by humans and non-human animals.

According to the present invention, types of food products include, but are not limited to, beverages, fermented foods, bakery products, health foods, and dietary supplements.

The present invention provides the use of a Kacip Fatima extract for preparing and enhancing TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene and beautifying skin appearance. Mara extract is obtained by extracting Kacip Fatima with a solvent, the solvent is water, alcohol, or a mixture of alcohol and water, which can be used to enhance TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene , SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene expression, and skin anti-wrinkle, skin whitening and skin moisturizing.

At the same time, the present invention is used to prepare a composition for enhancing the expression of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene and beautifying the appearance of skin, and it can also include an effective amount of Kaqi Huadi. Mala extract and a pharmaceutically acceptable carrier, the composition is a medicine, a food or a skin care product.

The detailed extraction method of the Kacip Fatima extract of the present invention will be described in detail below, and the Kacip Fatima extract's regulation of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, and FLG gene in skin keratinocytes will be described in detail below. , SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene expression test, as well as the test of reducing skin wrinkles, reducing skin melanin and reducing skin moisture loss, to confirm that the Kacip Fatima extract can enhance TGM gene, KRT Expression of gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene, and the effects of skin anti-wrinkle, skin whitening and skin moisturizing.

Example 1 Preparation method of Kacip Fatima extract of the present invention

In one embodiment of the present invention, the whole plant of Kacip Fatima is washed, and the whole plant of Kacip Fatima is extracted by an extraction solvent, and the extraction solvent is water, alcohol, or a mixture of alcohol and water , among which water is preferred, and Kacip Fatima is mixed with the extraction solvent in a weight ratio of 1-5:5-20, and is extracted in the solvent for 0.5-3 hours. After extraction, it was cooled to room temperature, and the crude extract was filtered through a 0.45-0.2 micron mesh to obtain a filtrate. Finally, the filtrate is concentrated under reduced pressure at 45-70° C. to obtain the Kacip Fatima extract of the present invention.

Example 2 The effect of the Kacip Fatima extract of the present invention in regulating the expression of TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene expression in keratinocytes

The present invention uses human primary epidermal keratinocytes (human primary epidermal keratinocytes, HPEK) to carry out the kaqifatima extract of the present invention to regulate transglutaminase 1 (Transglutaminase 1, TGM1 ) gene, keratin 1 (Keratin1, KRT1) ) gene, keratin 10 (Keratin10, KRT10 ) gene and keratin 14 (Keratin14, KRT14 ) gene, aquaporin 3 (Aquaporin 3, AQP3 ) gene, polykeratin microfilament (Filaggrin, FLG ) gene, parent antibody Dpp Homologue (Mothers against decapentaplegic homolog, SMAD ) gene, Glucocerebrosidase (Glucocerebrosidase, GBA ) gene, Hyaluronan synthase 2 (Hyaluronan synthase 2, HAS2 ) gene, and Hyaluronan synthase 3 (Hyaluronan synthase 3, HAS3 ) Gene expression analysis. The human primary skin keratinocytes were purchased from CELLnTEC (Switzerland) under the serial number HPEK-50, and the cells were cultured in serum-free keratinocyte-SFM (Gibco company, No. #10724-011, USA).

，其中△Ct=Ct_目標基因-Ct_ACTB(β-肌動蛋白，beta-actin)，再利用Excel軟體進行非成 對單尾student t-test以決定變異係數與是否在統計上具有顯著差異(*p值<0.05；**p值<0.01；***p值<0.001)。 Human primary keratinocytes were divided into five groups: (1) a control group containing only the cell culture medium for 24 hours (2) an experimental group added with 0.25 mg/mL of the Kacip Fatima extract of the present invention for 6 hours (3) The experimental group added with 0.125 mg/mL of the Kacip Fatima extract of the present invention for 6 hours, (4) the experimental group added with 0.25 mg/mL of the Kacip Fatima extract of the present invention and treated for 24 hours, and (5) ) in the experimental group in which 0.125 mg/mL of the Kacip Fatima extract of the present invention was added for 24 hours; wherein the Kacip Fatima extract of this example was extracted with water. Next, the keratinocytes were recovered with cell lysate (RB buffer, purchased from Geanaid, Taiwan, Cat No.RBD300-DG), and then RNA extraction reagent kit (purchased from Geneaid, Taiwan, Lot No.FC24015-G) was used. ) respectively collect the RNA in the two groups of cells, and then use ^{SuperScript®} III reverse transcriptase (purchased from Invitrogene, USA, No. 18080-051) to use 2000 ng of extracted RNA as a template and use primers to generate the corresponding cDNA products of reverse transcription of mRNA, Then, using ABI StepOnePlus ^™ Real-Time PCR system (Thermo Fisher Scientific Company, USA), and KAPA SYBR FAST (purchased from Sigma Company, USA, No. 38220000000), the two groups of reverse transcription products were quantified with the combination primers in Table 1, respectively. Quantitative real-time reverse transcription polymerase chain reaction (quantitative real-time reverse transcription polymerase chain reaction) test, the conditions are 95°C for 1 second, 60°C for 20 seconds, a total of 40 cycles. To quantify the mRNA expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene, wherein the quantitative value is taken from the threshold cycle number (Ct) , while the relative amount of mRNA of the target gene is derived from the equation

, where △Ct=Ct _{target gene} -Ct _ACTB (β-actin, beta-actin), and then use Excel software to perform unpaired one-tailed student t-test to determine whether the coefficient of variation is statistically significant ( *p-value <0.05; **p-value <0.01; ***p-value < 0.001).

The result that the Kacip Fatima extract of the present invention enhances the expression levels of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene is shown in FIG. 1 . . Previous studies have shown that TGM can form strong bonds between the cell membrane and structural proteins of keratinocytes, and can increase the strength and stability of the epidermis; KRT can form keratin filaments, and FLG can help keratin filaments assemble into strong The network of keratinocytes provides strength and elasticity to the skin; AQP increases the permeability of water in keratinocytes to increase the water content of keratinocytes; SMAD is a signaling factor related to the regulation of collagen expression; GBA is related to the maintenance of keratinocyte structure It is related to integrity; HAS will promote the ability of keratinocytes to secrete hyaluronic acid, make the skin stratum corneum structure complete and improve the skin barrier function, which can improve skin water retention . Effectively make keratinocytes secrete more moisturizing factors.

After the human primary keratinocytes are treated with the Kacip Fatima extract of the present invention, the expression level of TGM1 gene can be effectively increased by up to 2.7 times, the expression level of KRT1 gene can be increased by up to 4.4 times, and the expression level of KRT10 gene can be increased by up to 1.1 times. The expression level of KRT14 gene is up to 1.2 times, the expression level of AQP3 gene is up to 1.7 times, the expression level of FLG gene is up to 1.2 times, the expression level of SMAD1 gene is up to 1.1 times, the expression level of GBA gene is up to 1.6 times. The expression level of HAS2 gene was up to 2.1 times, and the expression level of HAS3 gene was up to 1.6 times. This result shows that the Kacip Fatima extract of the present invention can effectively enhance the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene and HAS3 gene, It can make the skin horny secrete more moisturizing factors, maintain the arrangement of keratinocytes, maintain the integrity of the stratum corneum structure, and improve the skin barrier function.

Example 3 Efficacy of Kacip Fatima extract of the present invention in reducing skin wrinkles

In order to confirm the effect of the Kacip Fatima extract of the present invention in reducing skin wrinkles, firstly, a Kacip Fatima mask added with 2% of the Kacip Fatima extract of the present invention was prepared; The mask of Mingzhi Fatima extract was used as the control group, and the essence of the mask was water, Xinxian ketone, hexylene glycol, 1,3-butanediol, Sanxian gum, thickener and Triethanolamine, and the Kacip Fatima extract in this example was extracted with water. Next, 8 subjects were recruited. After each subject washed his face in the morning and evening, the mask of the control group and the mask containing the Kacip Fatima extract of the present invention were applied to the left and right half of the face respectively. Take off the skin after 15 minutes, and massage with finger pulp to promote absorption. Before use and 4 weeks after use, use VISIA skin detector (CIS-VISIA.7 VISIA Complexion Analysis System, Canfield scientific, United States, serial number V71214) for testing For skin texture detection, a high-resolution single-eye camera is used with three light sources (all light-domain wavelengths, ultraviolet light, and polarized light sources) to photograph facial skin and obtain a clear image, and then use professional software for texture analysis.

Figure 2 shows the results of the Kacip Fatima extract of the present invention in reducing skin wrinkles. After using the mask containing the Kacip Fatima extract of the present invention, the skin wrinkles were significantly reduced by 20.8% compared with before use; at the same time, up to 87.5% of the subjects showed significant improvement after use; while those without the present invention The control group with Kacip Fatima extract decreased by only 7.3%. This result shows that the Kacip Fatima extract of the present invention can effectively reduce skin wrinkles and has a significant anti-wrinkle effect on the skin.

Example 4 Efficacy of Kacip Fatima extract of the present invention in reducing skin melanin

In order to confirm the effect of the Kacip Fatima extract of the present invention in reducing skin melanin, firstly, prepare a Kacip Fatima mask with 2% of the Kacip Fatima extract of the present invention; and a Kacip Fatima mask without the present invention The facial mask of Chifatima extract was used as the control group, and the essence of the facial mask contained water, Xinxian ketone, hexanediol, 1,3-butanediol, Sanxian gum, thickener and triethanolamine. , and the Kacip Fatima extract of this embodiment is extracted with water. Next, 8 subjects were recruited. After each subject washed his face in the morning and evening, the mask of the control group and the mask containing the Kacip Fatima extract of the present invention were applied to the left and right half of the face respectively. Remove the skin after 15 minutes, and massage with finger pulp to promote absorption. Before use and 4 weeks after use, perform skin melanin index skin treatment with CK Cutometer ^® dual MPA 580 multi-probe skin analyzer (CK electronic, Germany). Quality detection, which uses the principle of spectral absorption, with the MX18 probe to measure the color light of specific wavelengths related to melanin (green light source: 568nm+/-3nm, red light source: 660nm±-3nm, infrared light source: 880nm±-10nm) in the human body The amount of reflection on the skin, and the absorption of specific wavelengths by melanin to define the skin color, calculate the relative content of melanin in the skin. Taking the value of melanin before use as 100%, relative to the percentage obtained before use, it is the percentage of improvement after use.

Figure 3 shows the results of the Kacip Fatima extract of the present invention in reducing skin melanin. After using the mask containing the Kacip Fatima extract of the present invention, the melanin index was significantly reduced by 3.6% compared with before use, while the control group increased by 1.3%. The test subjects showed significant improvement after using the mask containing the Kacip Fatima extract of the present invention. This result shows that the Kacip Fatima extract of the present invention can effectively reduce the content of melanin in the skin and has a significant skin whitening effect.

Example 5 Efficacy of Kacip Fatima extract of the present invention in reducing skin moisture loss

In order to prove the effect of the Kacip Fatima extract of the present invention in reducing skin moisture loss, first, a Kacip Fatima mask added with 2% of the Kacip Fatima extract of the present invention was prepared; The mask of Kacip Fatima extract was used as the control group, and the essence of the mask was water, Xinxian ketone, hexanediol, 1,3-butanediol, Sanxian gum, thickener and triglycerides. ethanolamine, and the Kacip Fatima extract of this example was extracted with water. Next, 8 subjects were recruited. After each subject washed his face in the morning and evening, the mask of the control group and the mask containing the Kacip Fatima extract of the present invention were applied to the left and right half of the face respectively. Take off the skin after 15 minutes, and massage with finger pulp to promote absorption. Before use and 4 weeks after use, use CK Cutometer ^® dual MPA 580 multi-probe skin analyzer (CK electronic, Germany) to conduct skin moisture loss ( TEWL) skin quality detection, in which a cylindrical hollow probe with open ends is used to form a relatively stable detection environment on the skin surface. ) The water dissipated from the stratum corneum, the water vapor pressure gradient formed by the temperature and humidity of the upper and lower two sensors in the probe, and Fick's law (Fick's law) to calculate the TEWL value (unit in g/ hm ² indicates). Taking the TEWL value before use as 100%, relative to the percentage obtained before use, it is the percentage of improvement after use.

The results of the Kacip Fatima extract of the present invention in reducing skin moisture loss are shown in FIG. 4 . After using the mask containing the Kacip Fatima extract of the present invention, the water loss was significantly reduced by 14.5% compared to before use, and the control group only reduced by 5.2%. This result shows that the Kacip Fatima extract of the present invention can effectively reduce the loss of skin moisture and has a significant skin moisturizing effect.

To sum up, the Kacip Fatima extract of the present invention can effectively improve the expression of TGM1 gene, KRT1 gene, KRT10 gene, KRT14 gene, AQP3 gene, FLG gene, SMAD1 gene, GBA gene, HAS2 gene, and HAS3 gene. It can effectively reduce skin wrinkles, reduce skin melanin and reduce skin water loss, and can improve the expression of skin TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene, and skin anti-wrinkle , Whitening, moisturizing effect, so that the skin can form more moisturizing factors, maintain the integrity of the stratum corneum structure, and improve the skin barrier function. Therefore, the Kacip Fatima extract of the present invention can be used to prepare a composition for enhancing the expression of skin TGM gene, KRT gene, AQP gene, FLG gene, SMAD gene, GBA gene, and HAS gene and beautifying skin appearance, And the composition is a medicine, a food or a skin care product, which can be administered to an individual by oral administration, skin application and the like.

<110> Dajiang Biomedical Co., Ltd.

<120> Use of Kacip Fatima extract to improve skin elasticity, strength or stability

<130> 107B0403-I1

<160> 22

<170> PatentIn version 3.5

<210> 1

<211> 22

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 1

<210> 2

<211> 19

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 2

<210> 3

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 3

<210> 4

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 4

<210> 5

<211> 22

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 5

<210> 6

<211> 19

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 6

<210> 7

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 7

<210> 8

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 8

<210> 9

<211> 19

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 9

<210> 10

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 10

<210> 11

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 11

<210> 12

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 12

<210> 13

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 13

<210> 14

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 14

<210> 15

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 15

<210> 16

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 16

<210> 17

<211> 23

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 17

<210> 18

<211> 20

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 18

<210> 19

<211> 19

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 19

<210> 20

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 20

<210> 21

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 20

<210> 22

<211> 21

<212> DNA

<213> Artificial sequences

<220>

<223> Synthetic primers

<400> 20

Claims (9)

A use of a Kacip Fatima extract for preparing a composition for improving skin elasticity, strength or stability, wherein the Kacip Fatima extract is obtained by extracting a Kacip Fatima with a solvent, and The solvent is water. The use according to claim 1, wherein the composition achieves the skin barrier function by increasing the strength and stability of the epidermal layer of the skin. The use according to claim 2, wherein the composition achieves the function of increasing the strength and stability of the epidermal layer of the skin by increasing the expression level of transglutaminase (TGM) gene. The use as claimed in claim 2, wherein the composition achieves the skin barrier function by maintaining the integrity of the skin keratinous structure. The use according to claim 2, wherein the composition enhances the expression of glucocerebrosidase (Glucocerebrosidase, GBA), keratin (Keratin, KRT), hyaluronan synthase (Hyaluronan synthase, HAS) genes, and/ Or polykeratin microfilament (Filaggrin, FLG) gene expression to achieve the function of maintaining the integrity of the skin keratinous structure. The use according to claim 1, wherein the Kacip Fatima extract is obtained by extracting Kacip Fatima with a solvent for 0.5-3 hours. The use of claim 1, wherein the concentration of the Kacip Fatima extract is at least 0.125 mg/mL. The use according to claim 1, wherein the Kacip Fatima extract is extracted at 50°C-100°C. The use according to claim 1, wherein the composition is a medicine, a food or a skin care product.

Images